Brief: Poxel Announces Initiation Of Part 2 Of Phase 1A Study For Pxl065, Which Is Being Developed For Treatment Of Nash

Poxel SA

26/11/2018 07:21

Nov 26 (Reuters) - POXEL SA  POXEL.PA :
    * POXEL ANNOUNCES INITIATION OF PART 2 OF PHASE 1A STUDY FOR PXL065, WHICH IS BEING
DEVELOPED FOR
THE TREATMENT OF NASH
    * PXL065 DATA TO DATE SUGGEST POTENTIAL FOR A FAVORABLE PROFILE FOR TREATMENT OF NASH
    * "WE LOOK FORWARD TO ADVANCING BOTH OF OUR PROGRAMS FOR TREATMENT OF NASH INTO
PROOF-OF-CONCEPT
STUDIES IN 2019."
    * 2ND PART OF PHASE 1A STUDY WILL ENROLL 6 HEALTHY SUBJECTS PER GROUP, WITH PRIMARY
OBJECTIVE TO
ASSESS SAFETY AND TOLERABILITY AND A SECONDARY OBJECTIVE TO ASSESS DOSE PROPORTIONALITY
    * PIOGLITAZONE, A DRUG APPROVED FOR TREATMENT OF TYPE 2 DIABETES HAS DEMONSTRATED
THERAPEUTIC
EFFICACY FOR NASH, EVEN IN PATIENTS WITH ADVANCED FIBROSIS
    * THIS PHASE 1A TRIAL, WHICH WAS DISCUSSED WITH U.S. FDA IN PRE-INVESTIGATIONAL NEW DRUG
APPLICATION (IND) MEETING, WAS DESIGNED TO INCLUDE 2 SINGLE ORAL DOSES AND POTENTIALLY UP TO
THREE ADDITIONAL DOSES OF PXL065

Source text for Eikon:  ID:nBwbm13Jja 
Further company coverage:  POXEL.PA 

 (Gdynia Newsroom)
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))